H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on BNTC stock, giving a Buy rating on February 13.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors, notably the emerging clinical profile of BB-301 in oculopharyngeal muscular dystrophy and the upcoming data catalyst. He highlights that interim 12- and 24‑month results from the Phase 1b/2a study will be showcased as a late‑breaking poster at a major Muscular Dystrophy Association conference, underscoring growing scientific interest and potential validation of the program.
He also emphasizes that the predefined responder analysis framework for BB-301 is comprehensive, spanning patient‑reported outcomes, imaging-based swallow assessments, and functional swallowing tests, with all Cohort 1 completers reportedly qualifying as responders under stringent criteria. In his view, this multidomain, statistically grounded efficacy assessment, combined with the anticipated conference visibility and a $32 twelve‑month price target, supports maintaining a constructive outlook and a Buy recommendation on Benitec Biopharma shares.